Last reviewed · How we verify
ACYC vehicle
ACYC vehicle is a topical formulation designed to enhance the delivery and efficacy of acyclovir for localized antiviral treatment.
ACYC vehicle is a topical formulation designed to enhance the delivery and efficacy of acyclovir for localized antiviral treatment. Used for Herpes simplex virus infections (topical indication, likely cold sores or genital herpes).
At a glance
| Generic name | ACYC vehicle |
|---|---|
| Sponsor | Bausch Health Americas, Inc. |
| Drug class | Antiviral agent (topical formulation) |
| Target | Viral DNA polymerase (via acyclovir active ingredient) |
| Modality | Small molecule |
| Therapeutic area | Virology/Dermatology |
| Phase | Phase 3 |
Mechanism of action
ACYC vehicle represents a pharmaceutical formulation technology that improves the penetration and bioavailability of acyclovir at the site of application. By optimizing the vehicle or carrier system, this formulation aims to increase therapeutic efficacy while potentially reducing systemic exposure and adverse effects associated with traditional acyclovir delivery.
Approved indications
- Herpes simplex virus infections (topical indication, likely cold sores or genital herpes)
Common side effects
- Local irritation or burning at application site
- Erythema
- Pruritus
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACYC vehicle CI brief — competitive landscape report
- ACYC vehicle updates RSS · CI watch RSS
- Bausch Health Americas, Inc. portfolio CI